logo
Sign in

AMGEN INC

Thousand Oaks, CA · Biotech · Public

Innovative biopharmaceutical medicines including monoclonal antibodies, growth factors, and other biologics

New patent ·
Claim this profile

Follows are private to you and power your alerts

Updated · amgen.com

Sector
Biotech
Headquarters
Thousand Oaks, CA
Latest Form D
$2.3B offered, Mar 2011
Total capital
$2.4B
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$2.3B
1 Form D · last Mar 2011
188 months since last filing
Federal contracts
$34.9M
5 awards · Veterans Affairs, Health and Human S
Rank in Biotech#26 of 4373
Granted patents
27
13 pending · first 2026
Rank in peer group#1 of 1449

Capital timeline

20092011201320152017201920212023FEDERAL ↑EQUITY ↓Cumulative $2.4B$1.1M$7K$186K$26.4M$7.3M1st Form D$2.3B
2009201320172021FEDERAL ↑EQUITY ↓Cumulative $2.4B$1.1M$186K$26.4M$7.3M1st Form D$2.3B

Latest events

  • Federal contractHealth and Human S · Nplate Administration Kit Development For The Treatment Of Approved Indications, Including Acute Radiation Syndrome (ars)$7.3M
  • Federal contractHealth and Human S · This Contract Is To Advance The Development Of Romiplostim For Treatment Of Hematopoietic Subsyndrome-acute Radiation Syndrome (hs-ars) And Chemotherapy-induced Thrombocytopenia (cit) And A Drug Delivery Device Feasibility Project With An Option To$26.4M
  • Offering registeredForm D · SEC · 1st filing$2.3B
  • Federal contractVeterans Affairs · Drugs$186K
  • Federal contractVeterans Affairs · Exjade$7K
  • Federal contractVeterans Affairs · Medicine Required For Clinical Trial 551 For The Csp$1.1M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

17months

from AMGEN INC’s first federal award to its first private round.

First federal award · Sep 2009
Veterans Affairs · $1.1M
First Form D · Mar 2011
$2.3B · 1st Form D
Awards before first raise
3 awards

An association in public records, not a cause or a prediction.

Standing among 1449 peers

Line = median

Biotech · Molecule

  • Granted patents#1 · top 1%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • Anna S RichoExecutive OfficerNamed in SEC Form D filings
  • Anthony C. HooperExecutive OfficerNamed in SEC Form D filings
  • Brian M. McNameeExecutive OfficerNamed in SEC Form D filings
  • Cynthia M. PattonExecutive OfficerNamed in SEC Form D filings
  • David J BaltimoreDirectorNamed in SEC Form D filings
  • David W BeierExecutive OfficerNamed in SEC Form D filings
Show all 37 people
  • David W. MelineExecutive OfficerNamed in SEC Form D filings
  • David M. PiacquadExecutive OfficerNamed in SEC Form D filings
  • David J ScottExecutive OfficerNamed in SEC Form D filings
  • Fabrizio W BonanniExecutive OfficerNamed in SEC Form D filings
  • Francois D de CarbonnelDirectorNamed in SEC Form D filings
  • Frank J. Biondi, Jr.DirectorNamed in SEC Form D filings
  • Frank C HerringerDirectorNamed in SEC Form D filings
  • Frederick W GluckDirectorNamed in SEC Form D filings
  • Gilbert S. OmennDirectorNamed in SEC Form D filings
  • Greg C. GarlandDirectorNamed in SEC Form D filings
  • Jerry D ChoateDirectorNamed in SEC Form D filings
  • Jonathan M PeacockExecutive OfficerNamed in SEC Form D filings
  • J Paul ReasonDirectorNamed in SEC Form D filings
  • J. Paul ReasonDirectorNamed in SEC Form D filings
  • Judith C. PelhamDirectorNamed in SEC Form D filings
  • Kevin W SharerExecutive Officer, DirectorNamed in SEC Form D filings
  • Leonard D. SchaefferDirectorNamed in SEC Form D filings
  • Madhavan A. BalachandranExecutive OfficerNamed in SEC Form D filings
  • Michael A. KellyExecutive OfficerNamed in SEC Form D filings
  • Rebecca D HendersonDirectorNamed in SEC Form D filings
  • Robert A. BradwayExecutive Officer, DirectorNamed in SEC Form D filings
  • Robert A. EckertDirectorNamed in SEC Form D filings
  • Roger M PerlmutterExecutive OfficerNamed in SEC Form D filings
  • Ronald D SugarDirectorNamed in SEC Form D filings
  • R. Sanders WilliamsDirectorNamed in SEC Form D filings
  • Scott A. TrossExecutive OfficerNamed in SEC Form D filings
  • Sean E. HarperExecutive OfficerNamed in SEC Form D filings
  • Stuart A. TrossExecutive OfficerNamed in SEC Form D filings
  • Thomas J.W. DittrichExecutive OfficerNamed in SEC Form D filings
  • Tyler C. JacksDirectorNamed in SEC Form D filings
  • Vance D CoffmanDirectorNamed in SEC Form D filings

What it has protected

USPTO · 27 granted of 40
Show all 40 patent records

Related companies, and why

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .